A digital therapeutic is software that delivers a medical intervention directly to a patient, treating, managing, or preventing a disease the way a drug or medical device would. Unlike a typical health app that tracks steps or reminds you to drink water, a digital therapeutic is backed by clinical trial evidence, cleared or authorized by a regulatory body like the FDA, and in many cases requires a prescription. Think of it as medicine delivered through an app or software program instead of a pill.
How Digital Therapeutics Differ From Health Apps
The distinction matters because tens of thousands of health and wellness apps exist in app stores, and most of them face zero regulatory scrutiny. A meditation app or a calorie tracker can make broad wellness claims without proving anything in a clinical trial. Prescription digital therapeutics (PDTs) go through a fundamentally different process. They are evaluated for safety and effectiveness in randomized controlled trials, authorized through the FDA’s medical device review pathways, developed under Good Manufacturing Practices, and subject to post-marketing requirements similar to those for regulated pharmaceuticals.
That regulatory bar also means PDTs include stringent security and privacy controls that consumer wellness apps typically lack. The tradeoff is that FDA authorization can slow down software updates, since changes to a cleared medical product carry more oversight than pushing a patch to a fitness app.
What the Software Actually Does
Most digital therapeutics currently on the market deliver some form of cognitive behavioral therapy, or CBT, through a smartphone or tablet. CBT is a well-established psychological treatment that helps people identify and change unhelpful thought patterns and behaviors. Digital therapeutics translate those techniques into interactive software: guided exercises, real-time mood tracking, structured lessons, and prompts that walk a patient through cognitive restructuring (recognizing a distorted thought, evaluating the evidence for and against it, and replacing it with a more balanced one).
Not all digital therapeutics rely on CBT, though. Some use game-based neurocognitive training, sensory stimulation, or other evidence-based approaches depending on the condition they treat. The common thread is that the software itself is the treatment, not just a companion tool for an in-person therapy session. A patient might use the app independently at home, with periodic check-ins from a prescribing clinician.
FDA-Cleared Examples
Several digital therapeutics have received FDA clearance for specific conditions, which gives a concrete sense of where this category stands today:
- EndeavorRx: A video game-based treatment for children ages 8 to 12 with ADHD, designed to improve attention function through targeted sensory stimuli and motor challenges.
- reSET-O: A 12-week program for opioid use disorder that delivers CBT-based content alongside outpatient treatment and medication.
- SleepioRx: A CBT-based program for chronic insomnia that guides users through sleep restriction, stimulus control, and cognitive techniques.
- DaylightRx: A CBT program for generalized anxiety disorder and panic disorder.
- NightWare: A smartwatch-based system that detects nightmares through physiological signals and delivers gentle vibrations to disrupt them without waking the user.
- MamaLift Plus: A treatment for postpartum depression.
These products span behavioral health, sleep medicine, and neurodevelopmental conditions. The scope is expected to widen as more companies pursue clearance for chronic pain, substance use disorders, and other areas where behavioral interventions have strong evidence.
The Regulatory Framework
The FDA classifies digital therapeutics as Software as a Medical Device (SaMD), a category defined by an international group of regulators as “software intended to be used for one or more medical purposes that perform these purposes without being part of a hardware medical device.” In other words, the software itself is the device. It doesn’t need to be embedded in a physical piece of equipment to qualify.
Products go through the FDA’s standard medical device review pathways. Authorizations are based on randomized controlled trials showing statistically and clinically meaningful benefits on key outcomes relevant to the specific condition, such as treatment retention, symptom reduction, or abstinence rates. This is the same type of evidence standard applied to drugs seeking label claims, adapted for a software product.
How You Get One (and Who Pays)
Prescription digital therapeutics require a clinician’s order, just like a medication. But the infrastructure for prescribing and dispensing them is still catching up. Integration with electronic health records and ordering systems is not yet widely established, which means the process can feel clunky compared to filling a prescription at a pharmacy. Some manufacturers are working directly with health record platforms to build smoother workflows.
Coverage and reimbursement remain the biggest practical hurdle. As of the most recent policy landscape, there is no Medicare benefit category or physician fee schedule for digital therapeutics. The only public coverage comes through individual contracts with state Medicaid plans, and even that coverage is not mandatory the way it is for FDA-approved drugs enrolled in the Medicaid Drug Rebate Program. In April 2022, the Centers for Medicare and Medicaid Services created a billing code (A9291) for “prescription digital behavioral therapy,” which covers products using CBT and other behavior-modifying methods. But having a billing code and having guaranteed coverage are two different things.
On the commercial insurance side, payers can manage digital therapeutics under pharmacy claims, and some pharmacy benefit managers are beginning to evaluate them for formulary placement. The process mirrors how insurers assess new drugs: weighing clinical evidence, cost-effectiveness, and the needs of their member population. But adoption has been slow, and many patients still face out-of-pocket costs or limited access depending on their plan.
A Growing but Volatile Market
The digital therapeutics market is projected to grow by roughly $17.6 billion between 2026 and 2030, at an annual growth rate of about 24%. Those numbers reflect enormous optimism about the category’s potential. But the path hasn’t been smooth. Several early digital therapeutics companies have struggled financially or shut down, often because reimbursement challenges made it difficult to sustain a business even with a clinically validated, FDA-cleared product. Having regulatory approval doesn’t automatically translate to widespread adoption if insurers aren’t covering the product and physicians aren’t yet comfortable prescribing it.
The companies that have gained traction tend to be those that solved the distribution problem, either by securing payer contracts, partnering with health systems, or finding employer-sponsored health plan channels willing to cover the cost. For patients, this means availability varies significantly depending on where you live, what insurance you carry, and what condition you’re seeking treatment for.
What Makes This Category Distinct
Digital therapeutics sit at an unusual intersection. They are regulated like medical devices, evaluated like drugs, prescribed like medications, but delivered like apps. That hybrid identity creates both their promise and their friction. The promise is scalable, low-cost treatment that patients can access from home for conditions where demand for care far outstrips the supply of clinicians. The friction is that healthcare systems built around pills and procedures don’t yet have clean pathways for prescribing, dispensing, and paying for software-based treatments.
For patients, the practical takeaway is straightforward. If your clinician prescribes a digital therapeutic, you’re getting a software-based treatment that went through rigorous clinical testing and FDA review. It is not a wellness app with a medical veneer. Whether your insurance covers it, and how easily your doctor can prescribe it, depends on factors that are still being worked out across the healthcare system.